

“To evaluate the efficacy of Lacrimal Sac Leavage with Moxifloxacin 0.5% ophthalmic solution [4 Quin™ PFS, Entod Pharmaceuticals Ltd. (India)] as treatment of Post-Surgical Canaliculitis / Dacryocystitis” – June, 2013

ABSTRACT (DRAFT)

Authors: Dr. Hadi M Khazaei, Dr. Gagan Dudeja, Dr. Rohit Shetty

(Narayan Nethralaya, Post-Graduate Institute of Ophthalmology, Bangalore, India)

Acknowledgement: Entod Pharmaceuticals Ltd. (India)

Purpose: To evaluate the efficacy of Lacrimal Sac Leavage with Moxifloxacin 0.5% ophthalmic Solution as treatment of Post-Surgical Canaliculitis / Dacryocystitis.

Design: This is a parallel randomized interventional study.

Methods: Fifty Patient with Post-Surgical Canaliculitis / Dacryocystitis were enrolled in this parallel randomized interventional study, which were further categorized into 2 groups, the treatment group (Group A) receiving 0.5 mL lacrimal sac leavage with Moxifloxacin 0.5% ophthalmic solution 24 hours after surgical intervention for Chronic Dacryocystitis/Canaliculitis, and the control group (Group B) which had 0.5 mL of aqua destilata (placebo). Clinical observation of the eyes in each group was performed on the first until the sixth day after the inoculation using a clinical grading scale. On the sixth day, the eyes were examined for microbiological evaluations.

Results: The total clinical grading scores of each group were similar 24 hours after surgical intervention for Chronic Dacryocystitis ($P > 0.05$). The total clinical grading scores of Group A on the sixth day and the difference in total clinical scores on the first and the sixth day were shown to be significantly lower than that of Group B ($P < 0.05$). Microbiological analysis revealed that there was a lower bacterial count in Group A (mean = 1.16 ± 0.83 logCFU/0.1 mL) compared with Group B (mean = 3.04 ± 0.51 logCFU/0.1 mL).

Conclusions: Lacrimal Sac Leavage with Moxifloxacin 0.5% ophthalmic solution 24 hours after surgical intervention for Chronic Dacryocystitis appeared to be effective and safe.

Not for redistribution: No part of the content contained herein may be redistributed, copied, abstracted, disseminated, circulated or included as part of any other service or product. For all permissions/reprints requests, please contact scientificell@entodpharma.com